Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27768809 | 0.98 | GABRA5 (0.47) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| Hydrochloric Acid SCHEMBL1018925 | 0.98 | GABRA5 (0.47) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| Hydrochloric Acid SCHEMBL29642930 | 0.98 | GABRA5 (0.47) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| Trifluoroacetic Acid SCHEMBL13254839 | 0.87 | GABRA5 (0.43) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| SCHEMBL488817 | 0.86 | — | — | |
| SCHEMBL488899 | 0.86 | — | — | |
| SCHEMBL488818 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL28195837 | 0.85 | SLC6A1 (0.64) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| Hydrochloric Acid SCHEMBL30595524 | 0.85 | SLC6A1 (0.64) | GABRA5GABRB2GABRA1SLC6A1SLC6A12 | |
| SCHEMBL303265 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201909-A | Quinazoline derivative compound and use thereof | 株式会社沃若诺伊 | 2024-06-14 | — | — | CN | claimed |
| CN-112888674-B | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2023-06-30 | — | — | CN | claimed |
| WO-2017023975-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023984-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017024004-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023996-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023980-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023987-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023973-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017024010-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | claimed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| CN-1436175-A | Cyclic lactams as inhibitors of A beta-protein production | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-08-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | GABRA5 454/4885GABRB2 244/4885GABRA1 195/4885 |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | GABRA5 3181/4885GABRB2 3333/4885GABRA1 3528/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | GABRA5 2269/4885GABRB2 2676/4885GABRA1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.